CEO Pravin Dugel described 2025 as "a transformative year for Ocular Therapeutix" and highlighted the advancement of two registrational studies in wet AMD, SOL-1 and SOL-R. Dugel announced, "SOL-R has ...
Hosted on MSN
MindMed outlines 2026 Phase III trial readouts and advances MM120 commercialization with new CFO
Earnings Call Insights: Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 CEO Robert Barrow highlighted that MindMed remains "on track with enrollment with our three pivotal Phase III trials for our lead ...
Following meetings with the FDA and the European Medicines Agency's Paediatric Committee, Inozyme Pharma Inc (NASDAQ:INZY) updated its global development strategy for INZ-701, a treatment for ENPP1 ...
CEO Jim Brown emphasized the company’s focus on advancing larsucosterol, their lead asset for treating alcohol-associated hepatitis (AH). He highlighted the significant unmet need in this area, with ...
Cardiff Oncology Inc (NASDAQ:CRDF) provided a clinical update on the first release of data from its ONSEMBLE trial of onvansertib in combination with FOLFIRI/bev in patients with second-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback